Gary Greenstein’s Post

Grifols is honored to celebrate #Alpha1AwarenessMonth and #COPDAwarenessMonth. It is estimated that 90% of patients with alpha-1 are undiagnosed. AlphaID screening kits make it easy to rule out alpha-1 as a predisposition to a COPD diagnosis. HCPs can order fast, free, and accurate screening kits at https://lnkd.in/gcxpAQev. For those with COPD, test kits may now be ordered at https://lnkd.in/gShuJ36v The receipt of this free testing service does not create any expectation or obligation to purchase or use any product or service offered by any manufacturer. #COPDSmokeScreen #Alpha1Awareness #geneticcopd #alpha1screening #alphaidathome

Grifols is honored to celebrate #Alpha1AwarenessMonth and #COPDAwarenessMonth. It is estimated that 90% of patients with alpha-1 are undiagnosed. AlphaID screening kits make it easy to rule out alpha-1 as a predisposition to a COPD diagnosis. HCPs can order fast, free, and accurate screening kits at https://lnkd.in/d3fFz5Gd. For those with COPD, test kits may now be ordered at https://lnkd.in/efc9Rcaj The receipt of this free testing service does not create any expectation or obligation to purchase or use any product or service offered by any manufacturer. #COPDSmokeScreen #Alpha1Awareness #geneticcopd  #alpha1screening #alphaidathome

IMPACT is proud to announce that we have had three poster abstracts accepted at #AMCP2024: - Poster # E9: Health Plan Best Practices Highlight Opportunities for Enhancing Patient Outcomes in Diabetes Through Continuous Glucose Monitoring - Poster # D7: Patient Advocacy-led Educational Sessions for Payer Professionals Yields Increased Confidence and Planned Change in Sickle Cell Disease - Poster # L10: Impact of a Multi-Year Initiative for Managed Care Professionals to Increase their Understanding of Atopic Dermatitis #CGM #SickleCellDisease #AtopicDermatitis

VIDA's AI-driven mucus plug analysis will be featured in 5 #ATS2024 abstracts. In this analysis of #SARP patients by Peterson et al., a regional association between mucus plugging and downstream air trapping was evident in subjects with severe plugs. These results add to the growing evidence that plugs could be targeted with therapies to improve downstream air trapping in patients with asthma. https://hubs.ly/Q02wxnyz0 Meet with VIDA at ATS: https://hubs.ly/Q02wxrxs0 #mucusplugs #mucusplugging #asthma #digitalbiomarkers

Watch this on-demand webinar on endobronchial valves as a treatment option for severe COPD/emphysema patients. Dive into each of the interactive seminar modules to learn more about: Part 1 - The multidimensional management of patients with severe COPD Part 2 - Lung Volume Reduction for COPD Part 3 - Assessment of patients and treatment with endobronchial valves Part 4 - Which patients are good candidates for endobronchial valves Part 5 - Patient Case Studies Access ➡️ https://bit.ly/3WZ7nMb #COPD #emphysema #Pulmonx #ZephyrValves #DigitalLearning This is a non-Pulmonx link. Webinar sponsored by Pulmonx Corporation. Results may vary.

Empower your patient care with precision and insight! Introducing Amerimmune's Standard Immunophenotyping Panel (SIP) – your go-to for swift screening of immune disorders and vigilant monitoring of immunodeficiency. 🌐🔬 Plus, gain crucial insights into your patients' risk of serious complications from SARS-CoV-2. Elevate your diagnostic capabilities and enhance patient outcomes with Amerimmune's advanced healthcare solutions. 🛡️💙 #AmerimmuneSIP #HealthcareInnovation #Immunophenotyping

New data presented at #ATS2024 suggest that #BronchialRheoplasty (#BR) reduces mucus plugging in adults with #ChronicBronchitis (CB). Dr. Victor Kim’s research included 52 patients with symptomatic #CB who underwent bilateral BR procedures. After the Bronchial Rheoplasty, the mean mucus plugging score decreased by nearly one segment from 4.3 to 3.4. Additionally, the distal airway volume increased by 7.4%. #COPD symptoms were also improved, with mean changes from baseline to follow-up of 6.8 points on the COPD Assessment Test and 14.5 points on the St. George’s Respiratory Questionnaire. To learn more about the data, visit wb.md/3Vy8Fgf. To learn more about the RheOx System to treat the symptoms of chronic bronchitis, visit https://lnkd.in/gFiKHkw3. #AmericanThoracicSociety #ATS #RheOx #MucusPlug #ChronicBronchitis #PEF #RheOxSystem #MedEd #PulsedElectricFields Source: Bronchial Rheoplasty Unplugs Mucus in Patients With Chronic Bronchitis - Medscape - June 04, 2024. The RheOx® system is an investigational device in the United States and is limited by Federal (or United States) law to investigational use.

📌 Earlier diagnosis and more effective treatment of chronic kidney disease (CKD) can reduce patient and caregiver absenteeism, increase the ability to work and promote long-term productivity. 🌀   Learn more about the economic impact of CKD: https://learn.az/6187kk1DP   #ForKidneyHealth  Global Patient Alliance for Kidney Health AstraZeneca

A Targeted Approach Needed in COPD: Transforming patient outcomes in a complex disease like COPD relies on delivering the right options for each patient at the right time.      The complex mechanisms involved in COPD means there is no one optimal approach for the nearly 400 million people impacted. Advancing care will require a multi-faceted approach that addresses the needs of many different patients. It involves a commitment to scientific innovation to deepen our understanding of COPD and how to best address the many underlying drivers of this disease.     An article sharing the opinions of Caterina Brindicci, Maria Belvisi and MeiLan Han, lifts the curtain on how AstraZeneca is investing in COPD science and care and working to eliminate it as a leading cause of death. Check it out here: https://bit.ly/3UDc4ts     #WhatScienceCanDo 

🌍 Today is #WorldBronchiectasisDay! Let's raise awareness about this chronic lung condition affecting millions. At Spero we hope to raise awareness about this chronic lung condition by educating patients and clinicians. Spero is doing the important work of conducting research in this area of unmet need to advance new therapies and show compassion to bronchiectasis patients. Learn more from COPD Foundation: https://bit.ly/3XMCcUP. #WorldBronchiectasisDay2024